Sign up for email alert when new content gets added: Sign up
Multi-Cancer Early Detection (MCED) is a novel blood test that can detect cancer in its early stages, when it is most curable. MCED can detect a wide range of cancers, including those for which there are currently no screening approaches. In large-scale case-control and cohort studies, less invasive molecular biomarkers have been used to diagnose many malignancies early. These feasibility demonstrations highlight the possibility of lasting modification of present cancer screening paradigms. This opinion highlights the primary prospects and problems for Multicancer Early Detection test techniques in preclinical development and clinical validation. The authors offer particular methodologies and highlight significant questions for future research based on a varied set of early detection research viewpoints. A Multi-Cancer Early Detection (MCED) test used in conjunction with current screening could improve the number of cancers discovered by population screening, potentially improving clinical outcomes. Patients in the United States currently have access to only five cancer screening tests, which include testing for prostate, lung, breast, colorectal, and cervical cancers.
+44 7362049920
